IP Library Granted Patent US 6,936,640
Granted Patent B2
US 6,936,640 · App. 10/992,300 · Granted Aug 30, 2005

Biguanide/quaternary ammonium containing copolymeric biocides and use thereof in pharmaceutical compositions

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 6,936,640
App. No.
10/992,300
Granted
Aug 30, 2005
Kind
B2
Abstract

Biguanide/quaternary ammonium compounds and the use of same as antimicrobial agents in pharmaceutical compositions are described. The biguanide/quaternary ammonium compounds are useful in the preservation of pharmaceutical compositions, particularly ophthalmic pharmaceutical compositions and compositions for treating contact lenses. The compounds are especially useful for disinfecting contact lenses.

Claims (16)

1. A compound of the following formula:

wherein:

n is a whole number of from 1 to 100;

R 1 and R 2 are the same or different and are selected from the group consisting of alkyl (C 1 –C 10 ), aryl, and arylalkyl (C 3 –C 16 ), all of which may optionally contain one or more heteroatoms;

X is selected from the group consisting of alkyl (C 2 –C 16 ), aryl, and arylalkyl (C 3 –C 12 );

Y is selected from the group consisting of alkyl (C 2 –C 16 ), aryl, and arylalkyl (C 3 –C 12 ); and

Q is selected from the group consisting of alkyl (C 2 –C 20 ), aryl, arylalkyl (C 3 –C 20 ), amino alkyl (C 2 –C 20 ), alkenyl (C 2 –C 20 ), and alkylalkenyl (C 4 –C 20 ), all of which may optionally contain one or more quaternary ammonium moieties or heteroatoms; or a pharmaceutically acceptable salt thereof.

2. A compound according to claim 1 , wherein R 1 and R 2 are the same or different and are selected from the group consisting of alkyl (C 1 –C 6 ) and arylalkyl (C 3 –C 12 ); and Y is alkyl (C 2 –C 12 ).

3. A compound according to claim 2 , wherein n is 1 to 20; R 1 and R 2 are methyl; X is propyl; Y is hexyl; and Q is selected from the group consisting of trans-2-butene and bis-(N,N-dimethyl-N-trans-2-butenylamino)dodecane.

4. A pharmaceutical composition comprising an amount of a compound of claim 1 effective to preserve the composition from microbial contamination.

5. A pharmaceutical composition according to claim 4 , wherein the composition is an aqueous ophthalmic composition.

6. A pharmaceutical composition according to claim 4 , wherein the composition is an aqueous otic composition.

7. A pharmaceutical composition according to claim 4 , wherein the composition is utilized to treat contact lenses.

8. A composition for disinfecting contact lenses, comprising a disinfecting amount of a compound of claim 1 , and an ophthalmically acceptable vehicle therefor.

9. A method of disinfecting a contact lens, which comprises applying the composition of claim 8 to the lens.

10. A method of preserving pharmaceutical compositions from microbial contamination, which comprises including a preservative effective amount of a compound of claim 1 in the composition.

Assignments (3)
CONFIRMATORY DEED OF ASSIGNMENT EFFECTIVE APRIL 8, 2019 Recorded Dec 10, 2019
From: NOVARTIS AG
To: ALCON INC.
Reel/Frame 051454/0788 →
MERGER Recorded May 31, 2011
From: ALCON, INC.
To: NOVARTIS AG
Reel/Frame 026376/0076 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 18, 2004
From: MCQUEEN, NATHANIEL D.; PARK, JOONSUP
To: ALCON, INC.
Reel/Frame 016011/0515 →